Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Fluorine F 18 Piflufolastat

Review the clinical trials studying fluorine f 18 piflufolastat on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-19 of 19

Relugolix and Enzalutamide in Combination with Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
Status: Active
Location: 6 locations
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
Status: Active
Location: 2 locations
18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
REGN5678 before Surgery for Treating Patients with High-Risk Localized Prostate Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Image-guided Focal Brachytherapy with Combined 18F-DCFPyl PET/CT for the Treatment of Patients with Localized Prostate Cancer
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
REGN5678 and Cemiplimab for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
An Investigational Scan (18F-DCFPyL PET/CT) for the Detection of PSMA in Patients with HER2-Negative, Androgen Receptor Positive Breast Cancer
Status: Active
Location: 2 locations
A New Imaging Technique (18F-DCFPyL-PSMA PET/CT) for Detecting Cancer in Patients Planning to Receive 177Lu-Vipivotide Tetraxetan Therapy for Metastatic Castrate-Resistant Prostate Cancer
Status: Active
Location: 2 locations
PET/CT Characterization of Treatment Resistance in Patients with Metastatic Prostate Cancer
Status: Active
Location: 2 locations
18F-DCFPyL PSMA-PET Imaging for the Detection of Early Metastatic Prostate Cancer in Patients with High GC Test Scores, A Sub-aim of the VANDAAM Study (MCC #18523)
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
18 F-DCFPyL-PET/CT in Detecting PSMA Expression in Patients with Metastatic Triple Negative Breast Cancer
Status: Active
Location: University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa
PYLARIFY PET-CT for Detection of Metastasis in Pancreatic, Liver, or Breast Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Total-body PET/CT (EXPLORER) with Different Radiotracers for the Imaging of Prostate Cancer and Neuroendocrine Tumors
Status: Active
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
Status: Enrolling by Invitation
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Early Study to Identify Markers in Prostate Cancer to Assess Treatment
Status: Active
Location: 2 locations
Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Multimodal [18F]DCFPyL PET/MRI for Characterization of Solid Tumors
Status: Active
Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts